|
|
Post by omstem on Jan 11, 2022 6:05:29 GMT
For whatever is worth, I have invested my last couple investible of thousand dollars in ATHX to average down further. Don't know where the bottom is, but I am done investing in ATHX (BTW this is about 5% of my investment that I have been adding since 2015 when Ocata euphoria is done. (prepared to lose and write off or win a lotto kind of situation).
Is there going to be a reverse split? Ocata had done that while pundits have been predicting other way round. But this board has sanity and not blind following. Hope all of us do well. BTW I still made money on Ocata like 10% in 5 to 6 years.
GLTA
|
|
|
|
Post by selluwud on Jan 11, 2022 14:55:39 GMT
I'm still holding out for the stroke therapy trials being meaningful in Japan at least. We need to stay above $1.00 as much as possible to avoid delisting which would preclude a reverse split most likely.
|
|
|
|
Post by imz72 on Jan 21, 2022 0:34:47 GMT
Athersys (NASDAQ:ATHX) appoints Daniel A. Camardo as the company's CEO, effective February 14, 2022.
Mr. Camardo is a senior pharmaceutical and biotech executive with more than 25 years of commercial leadership experience. As CEO, he will lead forward to complete the development, approval, launch, and commercialization of the Company’s MultiStem (invimestrocel) cell therapy for the treatment of serious conditions, including ischemic stroke. Mr. William (B.J.) Lehmann, who most recently served as interim CEO will continue to serve as the President and COO, the position he held prior to his interim appointment. Mr. Camardo currently serves as Executive VP and Head of the Rare Disease and Inflammation Business Units and President, U.S. at Horizon Therapeutics. Athersys Press ReleaseDaniel Camardo - LinkedIn
 
|
|
|
|
Post by eitherhalf on Jan 21, 2022 11:08:14 GMT
WHOOOOOOOO HOOOOOO. ok, I am calm now. This company has taken me for drive, for real. Now lets see how the professional does it!!! Let's do this Daniel!
|
|
|
|
Post by imz72 on Jan 21, 2022 11:40:54 GMT
Form 8-K: Daniel Camardo's compensation termswww.sec.gov/Archives/edgar/data/1368148/000136814822000002/athx-20220114.htm•Mr. Camardo’s annual base salary rate during the term of his employment will be $600,000, subject to potential increases from time to time at the discretion of the Board or the Compensation Committee of the Board (the “Committee”). •A cash signing bonus of $250,000, to be paid within 30 days of the date Mr. Camardo commences employment with the Company (the “Commencement Date”). In the event that Mr. Camardo voluntarily terminates his employment within twelve months of the Commencement Date, he will be required to repay the full amount of the signing bonus. •As an inducement to Mr. Camardo’s acceptance of employment with the Company, the Company has determined to grant to Mr. Camardo an initial equity award that is intended to be an inducement award under Rule 5635(c)(4) of the Nasdaq Stock Market Listing Rules (the “Inducement Award”). The Inducement Award will be a stock option award to purchase 10,000,000 shares of the Company’s common stock at a per share exercise price equal to the closing price of a share of the Company’s common stock on the grant date. With regard to 4,000,000 shares, vesting of the Inducement Award will generally occur over a four-year period, with 25% of such portion of the award generally vesting on the first anniversary of the grant date and the remainder generally vesting monthly in substantially equal installments over the remaining 36 months. With regard to 6,000,000 shares, vesting of the Inducement Award will generally occur upon achievement of certain Company milestones, including FDA manufacturing process and marketing approvals, cumulative product sales, and business development and fundraising activities, as and when reasonably evaluated and determined by the Board in its sole discretion. The Inducement Award will generally have a 10-year term. •Mr. Camardo will be eligible to participate, during his employment, in the Company’s annual cash incentive compensation program (the “Annual Incentive Program”) on terms substantially similar to those that apply to other executive officers of the Company, with a target annual cash incentive opportunity equal to 60% of Mr. Camardo’s annual base salary (and no guaranteed minimum payment), subject to Company performance as designed annually for the Annual Incentive Program by the Board or the Committee. •Beginning in 2022, Mr. Camardo will be eligible to participate, during his employment, in the Company’s annual stock-based award program on terms substantially similar to those that apply to other executive officers of the Company. The terms of such awards will be determined annually at the discretion of the Board or the Committee. •While employed by the Company, Mr. Camardo will be eligible to participate in the Company’s employee benefit plans (including certain retirement and health and welfare benefit plans) on terms substantially similar to those that apply for other executive officers of the Company from time to time. Mr. Camardo will also be entitled to 20 days of paid vacation per year of full-time employment with the Company. •Mr. Camardo will be entitled to receive certain severance benefits under the terms of the Employment Agreement.
|
|
|
|
Post by selluwud on Jan 28, 2022 22:33:51 GMT
Wednesday Feb. 2nd Athersys (NASDAQ:ATHX) is scheduled to present a program milestone update titled "MultiStem Clinical Programs: An In-Depth Look." Some analysts have circled the event as a potential share price catalyst.
|
|
|
|
Post by eitherhalf on Jan 30, 2022 22:09:41 GMT
Weeeellll, here I am lookin for some money to get more shares. Empty pockets but hopefully I can turn over a couch cushion or two and come up with enough to bolster my position
|
|
|
|
Post by lcd on Jan 30, 2022 23:53:08 GMT
I hope the Wednesday presentation releases something of substance, but the lack of volume and continual share price decline over the past few months doesn't indicate to me that any important, positive news will be imminently released. I hope I am wrong.
|
|
|
|
Post by selluwud on Feb 2, 2022 19:41:04 GMT
I hope the Wednesday presentation releases something of substance, but the lack of volume and continual share price decline over the past few months doesn't indicate to me that any important, positive news will be imminently released. I hope I am wrong. Presentation must have been a fail (nothing new) but the lead up did get the close over a 1.00 yesterday. I didn't attend or watch myself. |
|
|
|
Post by imz72 on Feb 2, 2022 21:36:23 GMT
I hope the Wednesday presentation releases something of substance, but the lack of volume and continual share price decline over the past few months doesn't indicate to me that any important, positive news will be imminently released. I hope I am wrong. Presentation must have been a fail (nothing new) but the lead up did get the close over a 1.00 yesterday. I didn't attend or watch myself. Eventually ATHX closed at $1.02 today so we may call it a reasonable success  These were BJ's takeaway suggestions at the start of the presentation: |
|
|
|
Post by imz72 on Feb 2, 2022 22:35:45 GMT
BJ on MultiStem's business opportunity
CFO Ivor Macleod on Athersys' partnership strategy
|
|
|
|
Post by imz72 on Feb 4, 2022 21:07:00 GMT
MultiStem Clinical Programs: An In-Depth Look
Athersys is a clinical late-stage regenerative medicine company developing MultiStem® (invimestrocel) cell therapy. This investor presentation provides an in-depth look at the its current clinical programs in ischemic stroke, acute respiratory distress syndrome (ARDS), truama, additional programs in its portfolio with substantial potential therapeutic impact in areas of significant unmet needs. This program provides a clear understanding of the expected program milestones and why the Company is well-positioned to deliver on its mission to change the future of medicine. 00:00:00 Welcome and Forward Looking Statements 00:01:24 Introduction
00:07:40 Overview of MultiStem Cell Therapy 00:08:20 Clinical Program Portfolio 00:14:45 Ischemic Stroke Program 00:34:00 Hypothesis: MultiStem mechanism of action 00:52:05 Acute Respiratory Distress Syndrome (ARDS) Program 01:13:00 Other Programs: Preclinical Research 01:20:34 Summary 01:22:02 Question & Answer Session
|
|
|
|
Post by eitherhalf on Feb 5, 2022 0:17:47 GMT
Shook some coins out of that couch and plowed a bit more in at this level!! Still have faith and encouraged with the latest developments. Probably down a bit from here but I do expect that. I think we need a bit more time for ATHX to show its MUST-ARDS/s and watch our new man at the helm show his marketing chops.
|
|
|
|
Post by imz72 on Feb 7, 2022 21:38:05 GMT
|
|
|
|
Post by CM kipper007 on Feb 8, 2022 7:55:02 GMT
The slide deck of the 2.2.22 presentation has been posted. Many new slides: 7, 11, 15, 17-25, 27-28, 31-34, 37-42. s23.q4cdn.com/674737627/files/doc_downloads/2022/02-02-2022-ATHX-Program-Update.pdfSlide 37: Highlighting Other MultiStem Development Programs
<button disabled="" class="c-attachment-insert--linked o-btn--sm">Attachment Deleted</button> Slide 42: Key Takeaways from Clinical Program Update
<button disabled="" class="c-attachment-insert--linked o-btn--sm">Attachment Deleted</button> Always appreciate your hard work, IMZ. |
|
|
|
Post by imz72 on Feb 14, 2022 15:15:55 GMT
February 14, 2022: Healios Q4 2021 presentation ssl4.eir-parts.net/doc/4593/tdnet/2085483/00.pdfSlide 16: HLCM051 ARDS: ONE-BRIDGE Study Regenerative medicine product pre-application consultation* with the PMDA scheduled for the second half of March 2022
*A meeting to receive guidance and advice in relation to the adequacy etc. of approval application materials |
|
|
|
Post by imz72 on Feb 14, 2022 22:16:33 GMT
|
|
|
|
Post by selluwud on Feb 18, 2022 15:04:20 GMT
|
|
|
|
Post by selluwud on Feb 25, 2022 15:36:31 GMT
|
|
|
|
Post by Yelk on Mar 13, 2022 1:46:28 GMT
Whats the next major catalyst here? Been following company for years. Seems now or never eh.
|
|
